Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark
Our daily lives are full of products and processes based on fossil materials, or created using fossil energy sources such as oil and gas. To make significant progress in the green transition, we need ...
Novo Nordisk’s Hiring Binge Leaves Danish Firms Starved of Labor
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
FiercePharma14h
After studies flag possible link between Novo's Ozempic and rare eye disorder, Danish agency calls for probe
It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
24/7 Wall St4d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Pharmaceutical Technology2d
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Amycretin?
Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, 4 ...